Abstract: The present invention relates to the treatment of cancer using a combination of an inhibitor of the CD95/CD95L signaling system and an immunotherapeutic agent, e.g. a cancer vaccine or a checkpoint inhibitor. Another aspect of the invention is the prognosis of responsiveness of a cancer to the treatment with a combination of a CD95 inhibitor and an immunotherapeutic agent. Further disclosed are preparations and kits for use in these methods.

Abstract: The invention relates to poly(ADP-ribose)polymerase (PARP) homologs which have an amino acid sequence which has a) a functional NAD+ binding domain and b) no zinc finger sequence motif of the general formula CX2CXmHX2C in which m is an integral value from 28 or 30, and the X radicals are, independently of one another, any amino acid; and the functional equivalents thereof; nucleic acids coding therefor; antibodies with specificity for the novel protein; pharmaceutical and gene therapy compositions which comprise products according to the invention; methods for the analytical determination of the proteins and nucleic acids according to the invention; methods for identifying effectors or binding partners of the proteins according to the invention; novel PARP effectors; and methods for determining the activity of such effectors.

Abstract: The invention relates to poly(ADP-ribose)polymerase (PARP) homologs which have an amino acid sequence which has a) a functional NAD binding domain and b) no zinc finger sequence motif of the general formula CX2CXmHX2C in which m is an integral value from 28 or 30, and the X radicals are, independently of one another, any amino acid; and the functional equivalents thereof; nucleic acids coding therefor; antibodies with specificity for the novel protein; pharmaceutical and gene therapy compositions which comprise products according to the invention; methods for the analytical determination of the proteins and nucleic acids according to the invention; methods for identifying effectors or binding partners of the proteins according to the invention; novel PARP effectors; and methods for determining the activity of such effectors.

Abstract: The invention relates to poly(ADP-ribose)polymerase (PARP) homologs which have an amino acid sequence which has a) a functional NAD binding domain and b) no zinc finger sequence motif of the general formula CX2CXmHX2C in which m is an integral value from 28 or 30, and the X radicals are, independently of one another, any amino acid; and the functional equivalents thereof; nucleic acids coding therefor; antibodies with specificity for the novel protein; pharmaceutical and gene therapy compositions which comprise products according to the invention; methods for the analytical determination of the proteins and nucleic acids according to the invention; methods for identifying effectors or binding partners of the proteins according to the invention; novel PARP effectors; and methods for determining the activity of such effectors.

Abstract: The present invention relates to the use of an antibody or an antigen-binding fragment thereof with specific binding activity for human interleukin-4 for the prevention and/or treatment of cancer.

Abstract: The invention relates to novel 2-phenylbenzimidazoles of general formula (I) or (II), wherein the radicals have the meanings cited in the description, and to their tautomeric forms, possible enantiomeric and diastereomeric forms, to their prodrugs, and to possible physiologically compatible salts. The invention also relates to the production of said compounds and to their use.

Abstract: The invention relates to poly(ADP-ribose)polymerase (PARP) homologs which have an amino acid sequence which has a) a functional NAD+ binding domain and b) no zinc finger sequence motif of the general formula CX2CXmHX2C ?in which ?m is an integral value from 28 or 30, and the X radicals are, independently of one another, any amino acid; and the functional equivalents thereof; nucleic acids coding therefor; antibodies with specificity for the novel protein; pharmaceutical and gene therapy compositions which comprise products according to the invention; methods for the analytical determination of the proteins and nucleic acids according to the invention; methods for identifying effectors or binding partners of the proteins according to the invention; novel PARP effectors; and methods for determining the activity of such effectors.

Abstract: The present invention relates to the use of a combination of human interleukin-4 muteins and chemotherapeutic or pro-apoptotic agents for the prevention and/or treatment of cancer disease.

Abstract: The invention relates to compounds of the formula I and the tautomeric forms, possible enantiomeric and diasteromeric forms thereof, and prodrugs thereof, and use thereof as PARP inhibitors.

Abstract: The present invention relates to the use of phthalazine derivatives as inhibitors of the enzyme poly(ADP-ribose) polymerase or PARP (EC 2.4.2.30), to the use as inhibitors of PARP-homologous enzymes and, in particular, these phthalazine derivatives also show a selective inhibition of PARP-homologous enzymes.

Abstract: A method serves the purpose of introducing fuel and/or thermal energy into a gas stream flowing to a catalytic reactor. The gas stream flows in part through an exterior chamber and in part through an interior chamber, which is at least partially open in the flow direction and to which fuel is supplied. The partial streams are re-united after flowing through the two chambers and are fed to the catalytic reactor. In a starting phase of the still cold catalytic reactor, the fuel is burned in the interior chamber. During conventional normal operating modes of the warm catalytic reactor, the fuel is vaporized in the interior chamber. In a suitable device, the exterior chamber and the interior chamber are designed as two tube elements that are inserted into one another.

Abstract: Compounds of the formula I or II and their tautomeric forms, possible enantiomeric and diastereomeric forms, possible cistrans isomers on the rings in A and prodrugs thereof, pharmaceutical compositions containing these compounds and methods of treating neurodegenerative diseases or neuronal damage with these compounds.

Abstract: The present invention relates to novel benzimidazoles, their preparation and their use as inhibitors of the enzyme poly(ADP-ribose) polymerase or PARP (EC 2.4.2.30) for producing drugs.

Abstract: The invention relates to compounds of formula (I), wherein; either A1 or A2 represents CONH2, and the other radical A2 or A1 represents hydrogen, chlorine, fluorine, bromine, iodine C1-C6 alkyl, OH, nitro, CF3, CN, NR11R12, NH—CO—R13, O—C1-C4 alkyl; X1 can represent N and C—R2; X2, independent of X1, can represent N and C—R2; R2 can represent hydrogen, C1-C6 alkyl, C1-C4 alkyl-phenyl, phenyl; B can represent an unsaturated, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring having a maximum of 15 carbon atoms, an unsaturated, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms or 0 to 2 sulfur atoms, which can each still be substituted with an R4 and a maximum of 3 of the same or different radicals R5, and; R1, R4, R5, R11-R13 have the meanings as cited in claim No. 1.

Abstract: 2-Phenylbenzimidazoles and 2-phenylindoles of formula I wherein A is N or CH, R1 is hydrogen or alkyl which optionally carries an OR11 group, R11 is hydrogen or alkyl, R2 is hydrogen, chlorine, fluorine, bromine, iodine, alkyl, nitro, CF3, CN, NR21R22, NH—CO—R23, OR21, R21 and R22 are each hydrogen or alkyl, R23 is hydrogen, alkyl or phenyl, R3 is —(CH2)q—NR31R32, q is 0, 1, 2 or 3, R31 is hydrogen, alkyl, (CH2)rNR33R34, R32 is (CH2)rNR33R34, r is 2, 3, 4, 5 or 6, R33 and R34 are each hydrogen, alkyl or phenylalkyl wherein the phenyl ring is optionally substituted, or R33 and R34 and the nitrogen atom form a 3- to 8-membered ring, R4 is hydrogen, alkyl, chlorine, bromine, fluorine, nitro, cyano, NR41R42, NH—CO—R43, OR41, R41 and R42 are each hydrogen or alkyl, and R43 is alkyl or phenyl, are useful as inhibitors of poly(ADP-ribose)polymerase and for the production of drugs.

Abstract: The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.

Abstract: Compounds of the formula in which R1, R2 and R3 have the meanings stated in the description, are described. The novel substances are suitable for controlling diseases.

Abstract: Compounds of the formula Ia or IB where A is a saturated or monounsaturated heterocyclic, 4- to 8-membered ring which contains one or two nitrogen atoms, and their tautomeric forms, possible enantiomeric and diastereomeric forms, their prodrugs and possible physiologically tolerated salts are useful as inhibitors of the enzyme poly(ADP-ribose)polymerase.

Abstract: A method serves the purpose of introducing fuel and/or thermal energy into a gas stream flowing to a catalytic reactor. The gas stream flows in part through an exterior chamber and in part through an interior chamber, which is at least partially open in the flow direction and to which fuel is supplied. The partial streams are re-united after flowing through the two chambers and are fed to the catalytic reactor. In a starting phase of the still cold catalytic reactor, the fuel is burned in the interior chamber. During conventional normal operating modes of the warm catalytic reactor, the fuel is vaporized in the interior chamber. In a suitable device, the exterior chamber and the interior chamber are designed as two tube elements that are inserted into one another.

Abstract: Compounds of the formula Ia or IB where A is a saturated or monounsaturated heterocyclic, 4 - to 8-membered ring which contains one or two nitrogen atoms, and their tautomeric forms, possible enantiomeric and diastereomeric forms, their prodrugs and possible physiologically tolerated salts are useful as inhibitors of the enzyme poly(ADP-ribose)polymerase.